NYSE:OGNPharmaceuticals
Organon Buyout And POHERDY Approval Shape Returns And Valuation Outlook
Organon (NYSE:OGN) has agreed to be acquired by Sun Pharmaceutical Industries in an all cash deal valued at about $11.75b.
The transaction is expected to close in early 2027, after which Organon is set to be delisted from the NYSE.
Separately, Organon and Henlius have received European marketing approval for POHERDY, the first biosimilar to PERJETA.
For investors watching NYSE:OGN, these developments arrive after a sharp recent move in the share price. The stock closed at $13.29, with...